AXSM stock forecast, quote, news & analysis
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
Why Axsome Therapeutics (AXSM) Stock Is Down -23% in the Last 30 Days
Key Takeaways
- AXSM shares have fallen roughly 23% over the past 30 days, sliding from about $207.78 to $159.70.
- The selloff extended a broader multi-month pullback after commercial launch expectations for the company's CNS portfolio outpaced near-term results.
- Wall Street has tempered its outlook, with RBC Capital and Deutsche Bank lowering price targets amid a risk-off tone across biotech.
- Fundamentals remain growth-oriented: Q2 2026 net product revenue rose 46% year over year to roughly $218 million.
- Third-quarter 2026 results are scheduled for November 2, 2026, marking a key near-term catalyst.
Axsome Therapeutics (AXSM) Company Overview and Market Position
Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for central nervous system (CNS) conditions. Its commercial portfolio is anchored by Auvelity, an oral NMDA receptor antagonist approved for major depressive disorder (MDD) in adults and, since April 2026, for agitation associated with Alzheimer's disease dementia. The company also markets Sunosi for excessive daytime sleepiness tied to obstructive sleep apnea or narcolepsy, and Symbravo for the acute treatment of migraine in adults.
Beyond its three marketed products, Axsome is advancing a late-stage neuroscience pipeline that includes AXS-12 for narcolepsy with cataplexy, multiple solriamfetol programs, and earlier-stage candidates in schizophrenia and other indications. Investors follow the stock closely because of its rapid revenue growth, a large expanded sales force, and the potential of Auvelity to become a multi-billion-dollar franchise across MDD and Alzheimer's disease agitation.
Axsome Therapeutics (AXSM) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AXSM declined approximately 23%, moving from a close of about $207.78 to roughly $159.70. The drop was not a single-day event but a persistent slide, punctuated by a stretch of consecutive down sessions that marked the stock's longest losing streak since December 2018.
The recent weakness is part of a longer downturn. Over the last quarter, the stock has fallen roughly 28%, extending a retreat from its 52-week closing high of $255.17 reached in June 2026. Even with the pullback, AXSM remains well above its 52-week closing low of about $121, underscoring how far the shares ran before the current correction took hold.
What Drove AXSM Stock Price in the Last 30 Days
The 30-day decline was driven primarily by sentiment around the company's commercial launches. Analysts and investors had priced in rapid scaling of Auvelity, Sunosi, and Symbravo, and the shares had surged to record highs in the first half of 2026. When near-term launch metrics did not match those elevated expectations, the stock began to unwind.
Selling pressure was reinforced by analyst action. RBC Capital lowered its price target, and Deutsche Bank also trimmed its target, signaling that Wall Street was reassessing how quickly Axsome can scale its newer products and expand prescriber reach. A broader risk-off tone across the biotechnology sector, technical selling once the stock broke below key moving averages, and reports of insider sales added further downward momentum.
Notably, the decline occurred even as the underlying business continued to grow. In the second quarter of 2026, Axsome reported net product revenue of approximately $218 million, up 46% year over year, led by Auvelity at roughly $180 million. The gap between strong top-line growth and falling share prices reflects a reset of expectations rather than a deterioration in reported fundamentals.
What Drove AXSM Stock Performance Over the Last Quarter
The quarterly decline reflects a larger narrative shift. Axsome entered 2026 with considerable momentum, including FDA approval of Auvelity for Alzheimer's disease agitation and a raised peak-sales outlook for the franchise of at least $8 billion annually. Those catalysts helped push the stock to record highs before investors began scrutinizing execution more closely.
As the quarter progressed, concerns about gross-to-net discounts, elevated spending on an expanded commercial organization, and the pace of Symbravo adoption weighed on sentiment. Management has described Symbravo's gross-to-net discounts as temporarily elevated and expects improvement, while projecting that SG&A spending would plateau at second-quarter levels. Still, the market has favored near-term proof over longer-term potential, contributing to the extended correction.
Trending AI Robots
For traders looking to complement their own research with systematic strategies, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading bots. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary in trading strategy, timeframe, and performance metrics, giving users a way to explore different systematic approaches in a single place. The page is designed to help traders quickly identify the bots that are currently generating the most interest and activity. Exploring the section can provide additional perspective on how quantitative models are interpreting market conditions.
AXSM Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most immediate catalyst is Axsome's third-quarter 2026 earnings report on November 2, 2026. Investors will focus on Auvelity prescription trends, the trajectory of the Alzheimer's disease agitation launch, Sunosi and Symbravo growth, gross-to-net discount normalization, and any commentary on the path to cash-flow positivity.
Clinical milestones also matter. The company expects topline results from the Phase 3 ENGAGE trial of solriamfetol in binge-eating disorder in the second half of 2026, with the SUSTAIN trial in shift-work disorder anticipated in 2027. Regulatory developments, including progress on AXS-12 for narcolepsy with cataplexy, could further shape the narrative. Broader factors such as biotech sector sentiment, interest-rate expectations, and competitive dynamics in the CNS market will also influence how the stock trades from current levels.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AXSM sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for AXSM moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXSM as a result. In 57 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for AXSM turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 37 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AXSM entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
AXSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. AXSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AXSM's P/B Ratio (98.286) is slightly higher than the industry average of (2.988). P/E Ratio (-41.683) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (13.908) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services for pain and other nervous system
Industry Biotechnology